Key facts
- It has raised $84.0M; the latest was Later Stage VC in Nov 2025.
- Notable investors include Hangzhou Dongfang Jiafu Asset Management, Yinxinggu Capital, HaiBang Ventures, Shanghai Healthcare Capital, Hangzhou Linzhuo Industry Investment — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for HealSun Biopharm
- ·The full record, as it builds
Funding rounds
No funding rounds for HealSun Biopharm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HealSun Biopharm
Developer of biology technical services for antibody and recombinant protein drug development, designed to provide preclinical drug development services for global biopharmaceutical companies and biotechnology companies. The company's platform provides antibody drug analysis, transient protein expression, antibody recombinant protein CMC development and antibody conjugate drug development, enabling biopharmaceutical companies and biotechnology companies to speed up research and development and reduce overall costs.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2015
- Employees
- 180
- Website
- hs-biopharm.com/
- Ownership
- Privately Held (backing)
HealSun Biopharm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HealSun Biopharm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HealSun Biopharm in its N-PORT filings yet. We sweep new filings monthly.